The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.
 
Carla van Herpen
No Relationships to Disclose
 
Amaury Daste
Consulting or Advisory Role - BMS; Merck; Merus; MSD
Travel, Accommodations, Expenses - BMS; Merck
 
Virginia Arrazubi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck; MSD
Travel, Accommodations, Expenses - Merck; MSD
 
J.P. De Boer
Consulting or Advisory Role - MSD
 
Katerin Rojas
No Relationships to Disclose
 
Florian Clatot
Honoraria - AstraZeneca; AstraZeneca; BMS; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD
Consulting or Advisory Role - BMS; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; MSD; Novartis; Novartis; Nutricia; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; BMS; MSD; Novartis; Novartis; Novartis; Pfizer; Roche
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Amir Harandi
No Relationships to Disclose
 
Jessica Hellyer
Employment - Cancer Care Northwest
Consulting or Advisory Role - Tempus
Research Funding - AstraZeneca Oncology; BeiGene; Merus NV; Summit Pharmaceuticals
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD
 
Thibault Mazard
Honoraria - Takeda
Consulting or Advisory Role - Galapagos NV; Merck Serono; Pierre Fabre; SERVIER
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Pierre Fabre; Sanofi
 
Cesar Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Esma Saada
No Relationships to Disclose
 
Assuntina Sacco
Employment - Moores Cancer Center
Consulting or Advisory Role - Tempus
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Merus (Inst); Regeneron (Inst); Seagen (Inst); Toragen (Inst)
 
Eduardo Pennella
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Fabian Zohren
Employment - ImmunoGen; Merus NV; Pfizer
Leadership - ImmunoGen; Merus NV
Stock and Other Ownership Interests - ImmunoGen; Merus NV; Pfizer
 
Yu-Ming Shen
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Renee de Leeuw
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Jérôme Fayette
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Merus NV; Seagen; Takeda
Travel, Accommodations, Expenses - Merck Serono; Merck Sharp & Dohme